{"id":"W4399737488","doi":"10.1200/jco.2024.42.16_suppl.3091","title":"Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup>Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Somatostatin; Neuroendocrine tumors; Phase (matter); Internal medicine; Somatostatin Analogue; Phases of clinical research; Lanreotide; Oncology; Clinical trial; Cancer research; Pharmacology; Octreotide; Growth hormone; Hormone; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001821356,0.001266829,0.001408556,0.0003470494,0.0003058043,0.0007479332,0.0007729554,0.0009758282,0.01047966],"category_scores_gemma":[0.001011018,0.0004077486,0.001036998,0.0003745477,0.0007179302,0.0008162899,0.0003385055,0.002889383,0.001716242],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000885534,"about_ca_system_score_gemma":0.001745255,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006117125,"about_ca_topic_score_gemma":0.001821732,"domain_scores_codex":[0.9995536,0.0002349241,0.00002473488,0.00006258268,0.00004405938,0.00007993339],"domain_scores_gemma":[0.9994306,0.0001059223,0.000144392,0.00005404825,0.00004938559,0.0002155772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8011896,0.02195105,0.00353144,0.001728355,0.001326783,0.0002130988,0.0002097834,0.002592424,0.03734094,0.0007799985,0.01664245,0.1124941],"study_design_scores_gemma":[0.7276001,0.2466618,0.007523592,0.0001193746,0.0007775067,0.0003861806,0.00005755405,0.001574893,0.005404357,0.0006694337,0.009189948,0.00003528669],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9442647,0.0079316,0.003096472,0.001998943,0.0003787504,0.01688887,0.01146847,0.0004945495,0.01347777],"genre_scores_gemma":[0.9405689,0.003895862,0.008989336,0.002660757,0.0003069646,0.01689436,0.0182402,0.0001914918,0.008251989],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01047966,"threshold_uncertainty_score":0.03505796,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08718980111899502,"score_gpt":0.487025124728985,"score_spread":0.39983532360999,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}